Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes.
Ebaa Al OzairiMohammad IrshadEtab TaghadomLitty SojanJumana Al KandariDherar AlroudhanCarel W le RouxPublished in: Obesity (Silver Spring, Md.) (2023)
The SGLT2i and GLP1-RA agents on their own improved body weight and glycemia, but combining the medications resulted in more weight loss. Treatment intensification appears to result in benefits with no difference in severe adverse events.